Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • My alerts
  • Log in
  • Log out
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Intracellular Neutrophil Oxidants: From Laboratory Curiosity to Clinical Reality

Claes Dahlgren, Anna Karlsson and Johan Bylund
J Immunol June 1, 2019, 202 (11) 3127-3134; DOI: https://doi.org/10.4049/jimmunol.1900235
Claes Dahlgren
*Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, S-430 05 Gothenburg, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Karlsson
*Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, S-430 05 Gothenburg, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Karlsson
Johan Bylund
†Department of Oral Microbiology and Immunology, Institute of Odontology, Sahlgrenska Academy, University of Gothenburg, S-430 05 Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Johan Bylund
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The phagocyte NADPH oxidase is responsible for the neutrophil’s great capacity to produce reactive oxygen species (ROS). The NADPH oxidase can be assembled in the plasma membrane, as well as in membranes of intracellular vesicles, giving neutrophils the ability to direct ROS production to distinct subcellular sites. Neutrophil ROS contribute to microbial killing, trigger formation of neutrophil extracellular traps and appear to partake in inflammation control. Consequently, function-disrupting mutations in the NADPH oxidase lead to chronic granulomatous disease, characterized by severe infections and inflammatory disorders. Recent experimental data and description of a novel chronic granulomatous disease subtype (p40phox-deficiency) imply that ROS generated in intracellular compartments are key for NETosis and for controlling inflammatory signaling. We foresee boosted interest in intracellular ROS production. To fully understand where and how such ROS function, however, limitations of assay systems to measure ROS need to be appreciated, and the development of novel techniques/reagents would be highly useful.

Introduction

Reactive oxygen species (ROS) are chemically reactive metabolites of oxygen, and small amounts of such chemical species are produced in all living cells as by-products of aerobic metabolism. Phagocytic cells are equipped with a specialized enzyme system, the phagocyte NADPH oxidase (sometimes referred to as NOX2), that provides these cells with the capacity to produce much higher levels of ROS than those generated by mitochondria. The NADPH oxidase is an electron transport chain that reduces molecular oxygen to superoxide, which in turn serves as a precursor for formation of hydrogen peroxide and other secondary ROS. The induced ROS production because of activation of the NADPH oxidase is accompanied by a marked peak in cellular oxygen consumption, and the process is, therefore, often referred to as a “respiratory burst.” Among the human phagocytes, neutrophils are especially competent to produce ROS.

Components and localization of the NADPH oxidase

The basic structure of the phagocyte NADPH oxidase has been uncovered primarily through studies of cells from patients with chronic granulomatous disease (CGD; described in more detail below), which is a rare, inherited condition characterized by the inability of phagocytes to produce ROS because of a dysfunctional NADPH oxidase (1). The NADPH oxidase is a multicomponent enzyme consisting of a membrane-bound, heterodimeric b-type cytochrome (cytb558) comprising the subunits gp91phox and p22phox, together with several cytoplasmic subunits (p47phox, p40phox, and p67phox) (2). Upon activation, the cytosolic components translocate to the membrane and associate with the cytb558, together with a rac GTPase (Fig. 1).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

NADPH oxidase assembly and ROS generation at different sites in human neutrophils. The neutrophil NADPH oxidase is a multicomponent enzyme consisting of the membrane-bound part cytb558 (gp91phox/p22phox heterodimers; red) that upon activation associates to several cytoplasmic subunits. The cytb558 is localized in the plasma membrane as well as in granule membranes, mainly those of specific granules. Depending on which pool of cytb558 that the activated cytoplasmic subunits associate with, the ensuing ROS end up at different subcellular sites. When the plasma membrane-bound NADPH oxidase is activated, ROS are released extracellularly. When the granule-localized enzyme complex is activated, ROS are produced intracellularly, either in a phagosome (following phagolysosome fusion) and/or in a compartment formed after heterotypic granule fusion. New data indicate that the cytoplasmic subunit p40phox (green) is dispensable for extracellular ROS production, but vital for assembly and activation of the NADPH oxidase in intracellular membranes.

When the NADPH oxidase is active, cytoplasmic NADPH (generated by the hexose monophosphate shunt) provides electrons to the cytb558, which transports the electrons across the membrane to molecular oxygen on the opposite (noncytoplasmic) side. The process is dependent on the FAD unit of gp91phox. The electrons reduce oxygen to superoxide anion that spontaneously dismutates to hydrogen peroxide. These two primary ROS can then be further transformed into a wide variety of secondary ROS, (i.e., through reactions catalyzed by the neutrophil enzyme myeloperoxidase [MPO]) (3).

Localization of ROS production

Neutrophils are microbe killers, and their antimicrobial components are internally organized in different subcellular organelles, or granules. Part of the neutrophil cytb558 is localized in the plasma membrane, but the main portion is present in granule membranes, most notably those of the specific granules (4). Depending on which pool of the cytb558 that is engaged in formation of the active NADPH oxidase, the generated superoxide can either be secreted extracellularly from activation in the plasma membrane or produced inside membrane-enclosed intracellular compartments, tentatively by activation of specific granule-associated NADPH oxidase (5). The predicted site for intracellular ROS production would typically be the phagolysosome, formed after particle engulfment and fusion of specific granules (containing cytb558) with the phagosomal membrane (Fig. 1). True enough, neutrophils do produce massive amounts of ROS during phagocytosis of different microorganisms (6) at sites that are out of reach to large, membrane-impermeable ROS scavengers (e.g., superoxide dismutase [SOD]). In other words, the ROS are formed intracellularly (7, 8).

Intracellular ROS generation was long thought to be linked, by necessity, to phagocytosis. It is clear, however, that intracellular ROS can also be formed in the absence of phagosome formation [i.e., after stimulation of cells with the phorbol ester PMA (5, 9, 10) or with lectins, such as galectins or wheat germ agglutinin (11–13)]. The exact identity of the intracellular compartment where such ROS are produced is not yet known, but an organelle formed by heterotypic fusion of specific granules (providing the cytb558) and azurophil granules (providing MPO) has been suggested (14, 15) (Fig. 1). It is also clear that NADPH oxidase activation in intracellular membranes relies on slightly different signaling pathways, as compared with activation in the plasma membrane, suggesting that the NADPH oxidase in different membranes may be regulated by different cues (5, 9). Phagocyte ROS production is indeed crucial for our well-being, and, in all likelihood, the localization of ROS production will determine their functionality. Regarding the intracellular, nonphagosomal ROS, it seems reasonable that considerable ROS production in a cellular compartment (fused granules) devoid of any microbe to kill could substantially affect and direct cell signaling and function.

Triggers of ROS production at distinct cellular sites

Various types of stimuli can induce activation of the neutrophil NADPH oxidase, often resulting in production of ROS at distinct sites. For instance, high doses of neutrophil chemoattractants (such as formylated peptides) typically activate the plasma membrane-localized NADPH oxidase, which results in extracellular ROS release (16). There are a number of soluble stimuli that give rise to intracellular ROS production in combination with various levels of extracellular ROS release (5). PMA is, for example, a widely used soluble stimulus that directly activates protein kinase C, resulting in potent induction of ROS generation extracellularly as well as intracellularly, in nonphagosomal compartments (5, 9, 10). One group of soluble neutrophil activators of special interest in this regard is the galectins, endogenous lectins with affinity for lactosamine-containing glycoproteins. Galectins are present in a variety of inflammatory exudates and have many different effects on immune regulation (17, 18). At least three human galectins, galectin-1, -3, and -8, trigger distinct activation of the intracellular NADPH oxidase in addition to inducing extracellular ROS release. Interestingly, galectins only activate the NADPH oxidase if the cells have been primed prior to stimulation by, for example, in vivo transmigration (11, 13, 19).

With regards to the intracellular ROS triggered during phagocytosis, it is likely that the main part stems from the phagolysosomal compartment (see above), but experimental data show that other ROS-producing compartments are also present in cells exposed to particulate stimuli (20, 21). As will be discussed below, methodological shortcomings have prevented detailed analysis of the localization of ROS production during phagocytosis, suggesting that there is more to learn.

CGD

CGD is a rare immunodeficiency associated with bacterial and fungal infections, originally called “fatal granulomatous disease of childhood” when described some 60 y ago (22). Following the identification and study of more patients, the disease was shown to be associated with phagocytes that are unable to mount a respiratory burst and that are defective in microbial killing, thus explaining the predisposition to infection. As antibiotic regimes became more effective and CGD patients survived into adulthood, it was obvious that they were not only susceptible to infections but also suffered from a variety of inflammatory complications indicative of a malfunction in the mechanisms that control inflammation. It should be stressed that the clinical manifestations of CGD are quite varied (even when the causative mutations are identical), as both genetic and environmental factors likely influence the progression and severity of clinical symptoms (23, 24).

Classic CGD.

In classic CGD, neutrophils lack NADPH oxidase activity because of mutations in the genes encoding gp91phox (the majority of cases), p47phox, p67phox, or p22phox. Mutations in the gene for the cytosolic subunit p40phox have only recently been characterized and represent a distinct (nonclassic) subtype of CGD (see below). In vitro, neutrophils from patients with classic CGD display reduced microbial killing, resulting in recurrent and severe infections with certain bacterial and fungal species (1). Although phagocytes from many patients with classic CGD are entirely unable to form ROS, residual ROS production may occur for certain mutations, and as little as 1% of normal ROS production seems to confer milder disease and increased survival (25). To our knowledge, all classic CGD mutations affect the plasma membrane- and granule-localized NADPH oxidase equally, meaning that the ROS deficiency is manifested both extracellularly and intracellularly.

As mentioned above, increased susceptibility to infection is not the only clinical manifestation of CGD. Patients with classic CGD are also frequently plagued by various inflammatory disorders [e.g., granuloma formation, inflammatory bowel disease, and lupus-like symptoms (26–28)], comprising clear indications of dysregulated inflammatory reactions. This suggests that the ability to properly regulate inflammatory signaling is somehow dependent on NADPH oxidase-derived ROS, which will be discussed below.

A novel CGD subtype:p40phox deficiency.

Among the structural NADPH oxidase subunits, p40phox was for a long time never found among the mutated genes causing CGD. In 2009, a first patient was described with a genetic deficiency in this cytoplasmic subunit (29). Interestingly, this patient had no history of severe infections, but, instead, presented with granulomatous (Crohn) colitis, a condition that is indicative of an inability to limit inflammatory reactions. Quite recently, a description of 24 other p40phox-deficient patients from 12 families was presented by van de Geer and coworkers (30). Also, in these patients there was a strong association with hyperinflammation and significantly less severe (invasive) infections than in patients with classic CGD (30).

A most remarkable finding from patients with p40phox deficiency is that their neutrophils displayed a selective inability to generate intracellular ROS, whereas the ability to produce extracellular ROS was intact (29, 30). This cellular phenotype is markedly distinct from classic CGD but correlates well with experimental data from mice and cell lines, showing that p40phox is of minor importance for extracellular ROS production but critical for phagocytosis-induced (intracellular) ROS production (31, 32). Collectively, these findings imply that p40phox is of special importance for the NADPH oxidase when activated in internal membranes (Fig. 1). Clearly, p40phox deficiency stands out from deficiencies in the other oxidase subunits. Compared with classic CGD, p40phox deficiency is associated with a distinctly different neutrophil behavior in vitro and a pathologic condition seemingly characterized by less severe infections but just as pronounced inflammatory symptoms.

Mutations in nonoxidase genes.

Apart from mutations in genes for the structural components of the NADPH oxidase, deficiencies in certain auxiliary components may also render phagocytes incapable of mounting an oxidative burst. One very recent and exciting report from Iceland describes CGD-like pathologic conditions with particularly pronounced inflammatory problems in the gastrointestinal tract in eight patients, caused by a homozygous loss-of-function mutation in a gene named CYBC1 (for cytochrome b chaperone 1) (33). Almost simultaneously, another report described one Saudi Arabian patient with a different mutation in the same gene (34). Concurring with the Icelandic patients, this patient also had a clinical history that is compatible with CGD.

Not much is known about the protein CYBC1, also called EROS [essential for ROS (34)], except that it is a transmembrane protein which appears to function as a chaperone that facilitates assembly and correct folding of gp91phox and p22phox into a functional, heterodimeric cytb558 (33). Because gp91phox and p22phox in their monomeric forms are known to be degraded quite rapidly by the cytosolic proteasome (35), lack of CYBC1 should lead to decreased expression of cytb558 and, thus, impaired ROS production. This has been demonstrated to be the case in murine phagocytes (36) and was also corroborated in the two human studies (33, 34).

Interestingly, the relative importance of CYBC1 for cytb558 expression appears to be larger in monocytes/macrophages than in neutrophils (33, 36), which could imply that cells of the neutrophil lineage express additional chaperone proteins capable of partially backing up CYBC1. The infectious profile of the described patients (33, 34) seems slightly unusual as compared with classic CGD, with a possible inclination for intracellular pathogens (Mycobacterium tuberculosis/BCG and Listeria). CYBC1/EROS–deficient mice were also shown to display increased sensitivity to intracellular infections (36), and it is tempting to speculate that this reflects the central position of macrophages for controlling intracellular infections in particular. Whether CYBC1-deficiency could be viewed as a cell type-specific CGD (with complete penetrance in monocytes/macrophages and partial penetrance in neutrophils) is presently not clear, and, to our knowledge, nothing is known regarding where in neutrophils the remaining cytb558 is actually expressed and whether ROS production at different sites are equally affected.

Functional implications of intracellular ROS

As concluded by the pathological features of classic CGD, NADPH oxidase-derived ROS production is clearly central for our ability to fight infections, but it is also essential to control inflammatory reactions. By comparing the newly characterized p40phox CGD, in which neutrophils specifically lack the ability to form intracellular ROS, with classic CGD, in which ROS production is lacking extracellularly as well as intracellularly, a picture is emerging that implies that specific roles are played by neutrophil ROS generated in intracellular compartments.

Microbial killing in the phagosome.

Phagocytic uptake of microbes constitutes an important step in immune eradication of invading pathogens, and a number of microbes have evolved strategies to resist uptake or, alternatively, allowing phagocytic uptake but resisting the bactericidal arsenal of the phagosome, a characteristic of, for example, the intracellular pathogens Fracisella tularensis (37) and M. tuberculosis (38, 39). The logical link between phagocyte ROS production and microbial killing was established when it was shown that human phagocytes generate superoxide (40) and that such ROS production was lacking in phagocytes isolated from CGD patients (41, 42). Also, it was soon established that a significant portion of the ROS generated during phagocytosis was out of reach for extracellular scavengers, hence intracellular in location (7, 8), suggesting that they are produced inside the phagosome and contribute to killing at this site. The primary ROS produced by the NADPH oxidase, superoxide, is not very bactericidal per se, but its killing effect can be markedly increased by its transformation into hydrogen peroxide, especially in the presence of MPO and halides (43). These findings gave rise to the residing view that what is mostly responsible for the killing of microbes inside the phagosome is hypochlorous acid (44). This acid is formed by an MPO-catalyzed reaction between hydrogen peroxide and chloride, and it is very reactive and quite capable of killing microbes (45).

However, a number of observations challenge the view that intracellular hypochlorous acid is critical for microbial killing in the phagosome. For example, MPO-deficient individuals are less sensitive to infections than would be expected (46), at least much less than patients with classic CGD. Additionally, the MPO/hydrogen peroxide/halide system has been shown to affect host cell components rather than the ingested bacteria per se (47, 48). This confusion aside, if intracellular ROS production (with or without accompanying MPO processing) is indeed critical for phagosomal killing, the expectation would be that phagocytes lacking such ROS would display diminished killing activity. However, the p40phox deficiency described above, in which neutrophils specifically lack the ability to form ROS in intracellular compartments (including the phagosome), seems noticeably less associated with severe infection than classic CGD (29, 30). In addition, in vitro killing seems markedly more effective in p40phox-deficient neutrophils as compared with those from classic CGD patients (30).

One possible way to reconcile conflicting reports on the importance of intracellular ROS as microbe killers is to consider the idea that different microbes may be differently sensitive to specific ROS at specific sites. It could be that extracellular ROS are more important for bacterial killing than previously thought, which has, for example, been demonstrated for Escherichia coli strains resistant to phagocyte engulfment (49). It has also been suggested that the actual ROS are not at all responsible for bacterial killing in the phagosome, but that the primary role of the NADPH oxidase is, instead, to provide optimal ionic conditions and pH inside the phagosome for the neutrophil serine proteases (e.g., cathepsin G and elastase) to kill the microbes (50). Accordingly, the electron transport and the subsequent membrane polarization that control a charge compensatory flux of protons and other ions would be the most important function of the NADPH oxidase, and the actual killing would primarily be mediated by the serine proteases (51). Opposing this model, patients with Papillon–Lefèvre syndrome, the neutrophils of whom completely lack serine protease activity, are not particularly immunocompromised; this disease is not nearly as associated with infections as CGD (52). However, even if the electrogenic action of the NADPH oxidase cannot fully explain microbial killing in the phagosome, it may be that ion fluxes and pH regulation are of importance for other processes that are abnormal in CGD.

Clearly there is still much to learn regarding phagosomal killing and intracellular NADPH oxidase activity, and a detailed, mechanistical explanation for how ROS kill microbes inside phagosomes is still a rather open question (53–55).

Neutrophil extracellular trap formation.

In a seminal paper from 2004, neutrophils were shown to undergo a spectacular form of cell death to capture and eliminate microbes by casting out neutrophil extracellular traps (NETs) (56). This violent cell death, subsequently called NETosis, is distinct from necrosis and has in recent years attracted great interest (57–60). The NETs are web-like structures that consist of a backbone of nuclear material (DNA and histones) decorated with proteins originating from the neutrophil granules, such as MPO and elastase (56, 61). Although NETs were initially described as an antibacterial defense strategy, their regulatory potential in inflammation has become evident in a number of studies; diseases such as systemic lupus erythematosus, psoriasis, small vessel vasculitis, rheumatoid arthritis, gout, venous thrombosis, and cardiovascular disease all show the presence of NETs in vivo (62–64).

The best characterized example of NETosis describes a coordinated series of cellular events in which ROS production is a crucial step (65). Such ROS-dependent NETosis, requiring a functional NADPH oxidase, occurs as a result of interactions with a variety of microbes (61, 66–68). In vitro, the standard procedure to trigger NETosis by this ROS-dependent pathway is to expose cells to PMA. We recently showed that the ROS species crucial for PMA-triggered NETosis are those generated intracellularly in nonphagosomal compartments and that these ROS need to have been processed internally by MPO to drive NET formation (69). Because MPO and cytb558 are localized in different neutrophil granules (azurophil and specific granules, respectively) a likely scenario is that ROS and MPO become colocalized through heterotypic granule fusion (Fig. 1).

Our experimental findings recently gained support through the characterization of the p40phox-deficient CGD (see above) (30). Similar to classic CGD neutrophils, neutrophils lacking p40phox are unable to form NETs in response to PMA (30) despite the fact that these cells produce rather normal levels of extracellular ROS (29, 30). This finding fits perfectly with the idea that intracellular ROS production following PMA stimulation is truly central for the NETosis process (69). It is difficult to discern the exact identity of the intracellular ROS that affect NETs release by available techniques (described below and in the Tables). However, there is strong evidence that the NETs-triggering ROS species have to be processed by MPO intracellularly because MPO-deficient individuals are unable to form NETs (70) and only membrane-permeable MPO inhibitors and scavengers are capable of blocking NETosis (69).

Regulation of inflammatory signaling.

In general, ROS have the potential to react with a wide variety of biomolecules and take part in cell signaling. Initially, NADPH oxidase-derived ROS were argued to be essential for, for example, NF-κB activation leading up to the production of multiple proinflammatory cytokines. These conclusions were, however, largely based on experiments conducted with (often notoriously unspecific) NADPH oxidase inhibitors. In contrast, in vitro experiments with primary classic CGD phagocytes established that not only were these cells fully capable of activating NF-κB (71) or the NLRP3 inflammasome (72, 73), but they also produced significantly elevated levels of cytokines spontaneously as well as in response to stimulation (71, 72, 74–78). Exaggerated cytokine production has been confirmed in a cell line lacking gp91phox (74, 77), which implies that the inflammatory complications in CGD are not because of accompanying (subclinical) infections but, rather, represent an inherent hyper- (or even auto-) inflammatory phenotype. This fits perfectly well with the fact that classic CGD patients typically suffer from a wide variety of hyperinflammatory symptoms.

Pronounced hyperinflammatory pathologic condition is also seen in the p40phox-deficient CGD patients (29, 30), which suggests that the ROS that regulate inflammatory signaling are primarily the ones generated at intracellular sites. To our knowledge, whether p40phox-deficient phagocytes produce elevated levels of proinflammatory cytokines in vitro, similar to primary phagocytes from patients with classic CGD, has not been directly tested. Given the clinical features of patients with p40phox deficiency (29, 30), it is likely that p40phox-deficient phagocytes are equally hyperinflammatory as classic CGD phagocytes.

Because redox regulation of signaling pathways with a definite role of ROS as drivers of cytokine production is well established, the source of cytokine-inducing ROS is hardly the NADPH oxidase. If they were, nonphagocytic cells (or CGD phagocytes) would not be able to produce any proinflammatory cytokines at all. Instead, other cellular ROS sources, such as mitochondrial ROS, are more likely to promote NF-κB and inflammasome activation. We recently showed that classic CGD phagocytes (as well as a gp91phox-deficient cell line) displayed increased mitochondrial ROS (77), which could potentially reconcile the observations that ROS are critical for inflammatory signaling, yet CGD is a hyperinflammatory disease. To bring clarity to how (and where) NADPH oxidase-derived ROS modulate cytokine production and, thus, hyperinflammation, more emphasis needs to be given to identification of the source and localization of phagocyte ROS.

Comments on present techniques to measure and localize phagocyte ROS production

Over the years, a number of techniques have been developed to monitor phagocyte superoxide (Table I), hydrogen peroxide (Table II), or just undefined ROS production (Table III), all of which have both advantages and limitations (the Tables and (79) for a review). In the context of intracellular ROS production, some aspects of commonly used techniques are important to mention. The probe DHR-123 (80), used, for example, in the studies of p40phox-deficient neutrophils (29, 30) and the CYBC1 deficiency (33), is a membrane-permeable dye that gains in fluorescence (as measured by flow cytometry) when oxidized by ROS. Thus, in theory, DHR-123 mainly detects intracellular ROS. However, extracellular hydrogen peroxide produced by the plasma membrane-localized NADPH oxidase may diffuse across membranes to react with DHR-123 intracellularly (81). Also, ROS from other cellular sources, such as mitochondria (77), may contribute to DHR-123 fluorescence. There are, accordingly, risks for overestimation of NADPH oxidase-derived intracellular ROS using this probe. Moreover, oxidation of DHR-123 is, in part, dependent on the granule enzyme MPO (80), but the extent of the MPO dependency of this dye is, to our knowledge, not entirely clarified. Thus, it is clear that in order for the signals generated by dyes like DHR-123 to reflect intracellular NADPH oxidase-derived ROS, membrane-impermeable ROS scavengers should be added and MPO inhibitors (such as azide) should be avoided in the experimental set-up. Another rhodamine-based probe (R19-S) was recently introduced to directly measure the production of MPO-derived hypochlorous acid, and the dye has been used to determine phagosomal ROS activity (82). It should be noticed, however, that most of the fluorescence signal detected during phagocytosis of opsonized zymosan was recovered in cell supernatants, indicating that it is the result of extracellular reactions (82), possibly because of limited membrane permeability of the probe.

View this table:
  • View inline
  • View popup
Table I. Techniques to measure cellular production of superoxide anions
View this table:
  • View inline
  • View popup
Table II. Techniques to measure cellular production of hydrogen peroxide
View this table:
  • View inline
  • View popup
Table III. Techniques to measure cellular production of nondefined ROS

To determine the subcellular localization of neutrophil ROS production, luminol/isoluminol–based techniques are, sometimes, better alternatives than DHR-123. These techniques are based on the excitation of luminol or isoluminol by superoxide anion, generating detectable chemiluminescence (CL). Luminol, the most commonly used CL probe, is cell permeable and can be used to measure intracellular ROS. However, to achieve selectivity, it is crucial to add membrane-impermeable ROS scavengers (such as SOD and catalase) to neutralize extracellular ROS (79, 83). The related CL probe isoluminol differs from luminol only in the position of the amino group on the phthalate ring of the molecule, making it membrane impermeable. Isoluminol can thus be used to selectively determine extracellularly released ROS (79, 83). Both luminol and isoluminol are completely dependent on the processing of ROS by a peroxidase; the activity of endogenous MPO is absolutely critical for the detection of intracellular ROS (69), whereas the isoluminol-amplified system should contain an exogenous peroxidase (preferentially HRP) in order for the CL signal not to be critically dependent on released cellular MPO.

For detailed analyses of neutrophil ROS production, it is recommendable to use complementary methods, taking into account their limitations and paying close attention to methodological details. The future development of novel techniques and reagents along the lines outlined in Erard et al. (84) would, however, be a great contribution to the field.

Conclusions

The research community is increasingly willing to accept the idea that part of the ROS generated during the neutrophil respiratory burst is in fact produced and retained intracellularly and often generated independently of phagocytosis and phagolysosome formation. In light of the clinical phenotype of the patients with p40phox CGD and the experimental findings using their neutrophils, we foresee an increased future interest in these particular ROS. Judging by the clinical picture of the patients with p40phox CGD (highly inflamed but largely devoid of severe invasive infections) as compared with that of patients with classic CGD, it seems that intracellular ROS are specifically important for controlling inflammatory reactions but, surprisingly, not particularly important for microbe killing. The contribution to phagolysosomal killing of a p40phox-independent, plasma membrane-localized NADPH oxidase is, from this perspective, an interesting notion well worth examining.

It is clear that granule-localized ROS are vital for the expulsion of NETs in vitro, but how and exactly where these ROS drive NETosis is still not established. If and how ROS-dependent NET formation truly contributes to health and disease is a matter of some controversy (85). However, the fact that neutrophils treated with cell-permeable MPO inhibitors or scavengers of intracellular, MPO-processed ROS failed to generate NETs (69), as did neutrophils from patients with p40phox CGD (30), inspires further exploration of this question in animal models.

We look forward to the development of methodologies to measure intracellular NADPH oxidase-derived ROS independently of MPO. This would allow for more detailed characterization of the subcellular compartment(s) in which intracellular ROS are produced and, hopefully, facilitate the unraveling of mechanism(s) whereby they mediate their cellular effects and regulate inflammation. Because of the methodological difficulties in measuring intragranular ROS today (especially in a clinical setting), it is possible that specific defects in the generation of intragranular ROS may be under-detected among hyper- or autoinflammatory disorders. It will be truly exciting to follow this field of investigation in the years ahead.

Disclosures

The authors have no financial conflicts of interest.

Acknowledgments

We thank all past and present members of the Phagocyte Research Group at the Sahlgrenska Academy for valuable discussions about neutrophil physiology in general and ROS production in particular.

Footnotes

  • This work was supported by grants from the Swedish Medical Research Council, the Swedish Heart-Lung Foundation, the King Gustaf V 80-Year Foundation, the Patent Revenue Fund for Research in Preventive Odontology, and the Swedish government under the ALF and TUA agreements.

  • Abbreviations used in this article:

    CGD
    chronic granulomatous disease
    CL
    chemiluminescence
    MPO
    myeloperoxidase
    NET
    neutrophil extracellular trap
    ROS
    reactive oxygen species
    SOD
    superoxide dismutase.

  • Received February 25, 2019.
  • Accepted March 25, 2019.
  • Copyright © 2019 by The American Association of Immunologists, Inc.

References

  1. ↵
    1. Holland, S. M.
    2013. Chronic granulomatous disease. Hematol. Oncol. Clin. North Am. 27: 89–99, viii.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Thomas, D. C.
    2018. How the phagocyte NADPH oxidase regulates innate immunity. Free Radic. Biol. Med. 125: 44–52.
    OpenUrl
  3. ↵
    1. Klebanoff, S. J.
    2005. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77: 598–625.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Borregaard, N.,
    2. J. M. Heiple,
    3. E. R. Simons,
    4. R. A. Clark
    . 1983. Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: translocation during activation. J. Cell Biol. 97: 52–61.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Bylund, J.,
    2. K. L. Brown,
    3. C. Movitz,
    4. C. Dahlgren,
    5. A. Karlsson
    . 2010. Intracellular generation of superoxide by the phagocyte NADPH oxidase: how, where, and what for? Free Radic. Biol. Med. 49: 1834–1845.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bylund, J.,
    2. P. A. Campsall,
    3. R. C. Ma,
    4. B. A. Conway,
    5. D. P. Speert
    . 2005. Burkholderia cenocepacia induces neutrophil necrosis in chronic granulomatous disease. J. Immunol. 174: 3562–3569.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Root, R. K.,
    2. J. Metcalf,
    3. N. Oshino,
    4. B. Chance
    . 1975. H2O2 release from human granulocytes during phagocytosis. I. Documentation, quantitation, and some regulating factors. J. Clin. Invest. 55: 945–955.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Root, R. K.,
    2. J. A. Metcalf
    . 1977. H2O2 release from human granulocytes during phagocytosis. Relationship to superoxide anion formation and cellular catabolism of H2O2: studies with normal and cytochalasin B-treated cells. J. Clin. Invest. 60: 1266–1279.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Karlsson, A.,
    2. J. B. Nixon,
    3. L. C. McPhail
    . 2000. Phorbol myristate acetate induces neutrophil NADPH-oxidase activity by two separate signal transduction pathways: dependent or independent of phosphatidylinositol 3-kinase. J. Leukoc. Biol. 67: 396–404.
    OpenUrlPubMed
  10. ↵
    1. Lundqvist, H.,
    2. P. Follin,
    3. L. Khalfan,
    4. C. Dahlgren
    . 1996. Phorbol myristate acetate-induced NADPH oxidase activity in human neutrophils: only half the story has been told. J. Leukoc. Biol. 59: 270–279.
    OpenUrlPubMed
  11. ↵
    1. Almkvist, J.,
    2. C. Dahlgren,
    3. H. Leffler,
    4. A. Karlsson
    . 2002. Activation of the neutrophil nicotinamide adenine dinucleotide phosphate oxidase by galectin-1. J. Immunol. 168: 4034–4041.
    OpenUrlAbstract/FREE Full Text
    1. Karlsson, A.
    1999. Wheat germ agglutinin induces NADPH-oxidase activity in human neutrophils by interaction with mobilizable receptors. Infect. Immun. 67: 3461–3468.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Karlsson, A.,
    2. P. Follin,
    3. H. Leffler,
    4. C. Dahlgren
    . 1998. Galectin-3 activates the NADPH-oxidase in exudated but not peripheral blood neutrophils. Blood 91: 3430–3438.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Björnsdottir, H.,
    2. D. Granfeldt,
    3. A. Welin,
    4. J. Bylund,
    5. A. Karlsson
    . 2013. Inhibition of phospholipase A(2) abrogates intracellular processing of NADPH-oxidase derived reactive oxygen species in human neutrophils. Exp. Cell Res. 319: 761–774.
    OpenUrl
  14. ↵
    1. Björnsdottir, H.,
    2. A. Welin,
    3. C. Dahlgren,
    4. A. Karlsson,
    5. J. Bylund
    . 2015. Quantification of heterotypic granule fusion in human neutrophils by imaging flow cytometry. Data Brief 6: 386–393.
    OpenUrl
  15. ↵
    1. Dahlgren, C.,
    2. M. Gabl,
    3. A. Holdfeldt,
    4. M. Winther,
    5. H. Forsman
    . 2016. Basic characteristics of the neutrophil receptors that recognize formylated peptides, a danger-associated molecular pattern generated by bacteria and mitochondria. Biochem. Pharmacol. 114: 22–39.
    OpenUrl
  16. ↵
    1. Brinchmann, M. F.,
    2. D. M. Patel,
    3. M. H. Iversen
    . 2018. The role of galectins as modulators of metabolism and inflammation. Mediators Inflamm. 2018: 9186940.
    OpenUrl
  17. ↵
    1. Johannes, L.,
    2. R. Jacob,
    3. H. Leffler
    . 2018. Galectins at a glance. J. Cell Sci. 131: jcs208884.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Carlsson, S.,
    2. C. T. Oberg,
    3. M. C. Carlsson,
    4. A. Sundin,
    5. U. J. Nilsson,
    6. D. Smith,
    7. R. D. Cummings,
    8. J. Almkvist,
    9. A. Karlsson,
    10. H. Leffler
    . 2007. Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface. Glycobiology 17: 663–676.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Robinson, J. M.
    2008. Reactive oxygen species in phagocytic leukocytes. Histochem. Cell Biol. 130: 281–297.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Serrander, L.,
    2. J. Larsson,
    3. H. Lundqvist,
    4. M. Lindmark,
    5. M. Fällman,
    6. C. Dahlgren,
    7. O. Stendahl
    . 1999. Particles binding beta(2)-integrins mediate intracellular production of oxidative metabolites in human neutrophils independently of phagocytosis. Biochim. Biophys. Acta 1452: 133–144.
    OpenUrlPubMed
  21. ↵
    1. Bridges, R. A.,
    2. H. Berendes,
    3. R. A. Good
    . 1959. A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndrome. AMA J. Dis. Child. 97: 387–408.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Segal, B. H.,
    2. T. L. Leto,
    3. J. I. Gallin,
    4. H. L. Malech,
    5. S. M. Holland
    . 2000. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79: 170–200.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Segal, B. H.,
    2. P. Veys,
    3. H. Malech,
    4. M. J. Cowan
    . 2011. Chronic granulomatous disease: lessons from a rare disorder. Biol. Blood Marrow Transplant. 17(1, Suppl.): S123–S131.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Kuhns, D. B.,
    2. W. G. Alvord,
    3. T. Heller,
    4. J. J. Feld,
    5. K. M. Pike,
    6. B. E. Marciano,
    7. G. Uzel,
    8. S. S. DeRavin,
    9. D. A. Priel,
    10. B. P. Soule, et al
    . 2010. Residual NADPH oxidase and survival in chronic granulomatous disease. N. Engl. J. Med. 363: 2600–2610.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Henrickson, S. E.,
    2. A. M. Jongco,
    3. K. F. Thomsen,
    4. E. K. Garabedian,
    5. I. P. Thomsen
    . 2018. Noninfectious manifestations and complications of chronic granulomatous disease. J. Pediatric Infect. Dis. Soc. 7(Suppl. 1): S18–S24.
    OpenUrl
    1. Johnston, R. B. Jr.
    . 2001. Clinical aspects of chronic granulomatous disease. Curr. Opin. Hematol. 8: 17–22.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Rosenzweig, S. D.
    2008. Inflammatory manifestations in chronic granulomatous disease (CGD). J. Clin. Immunol. 28(S1, Suppl. 1): S67–S72.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Matute, J. D.,
    2. A. A. Arias,
    3. N. A. Wright,
    4. I. Wrobel,
    5. C. C. Waterhouse,
    6. X. J. Li,
    7. C. C. Marchal,
    8. N. D. Stull,
    9. D. B. Lewis,
    10. M. Steele, et al
    . 2009. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 114: 3309–3315.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. van de Geer, A.,
    2. A. Nieto-Patlán,
    3. D. B. Kuhns,
    4. A. T. Tool,
    5. A. A. Arias,
    6. M. Bouaziz,
    7. M. de Boer,
    8. J. L. Franco,
    9. R. P. Gazendam,
    10. J. L. van Hamme, et al
    . 2018. Inherited p40phox deficiency differs from classic chronic granulomatous disease. J. Clin. Invest. 128: 3957–3975.
    OpenUrl
  29. ↵
    1. Bagaitkar, J.,
    2. E. A. Barbu,
    3. L. J. Perez-Zapata,
    4. A. Austin,
    5. G. Huang,
    6. S. Pallat,
    7. M. C. Dinauer
    . 2017. PI(3)P-p40phox binding regulates NADPH oxidase activation in mouse macrophages and magnitude of inflammatory responses in vivo. J. Leukoc. Biol. 101: 449–457.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Ellson, C. D.,
    2. K. Davidson,
    3. G. J. Ferguson,
    4. R. O’Connor,
    5. L. R. Stephens,
    6. P. T. Hawkins
    . 2006. Neutrophils from p40phox-/- mice exhibit severe defects in NADPH oxidase regulation and oxidant-dependent bacterial killing. J. Exp. Med. 203: 1927–1937.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Arnadottir, G. A.,
    2. G. L. Norddahl,
    3. S. Gudmundsdottir,
    4. A. B. Agustsdottir,
    5. S. Sigurdsson,
    6. B. O. Jensson,
    7. K. Bjarnadottir,
    8. F. Theodors,
    9. S. Benonisdottir,
    10. E. V. Ivarsdottir, et al
    . 2018. A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease. Nat. Commun. 9: 4447–4455.
    OpenUrl
  32. ↵
    1. Thomas, D. C.,
    2. L. M. Charbonnier,
    3. A. Schejtman,
    4. H. Aldhekri,
    5. E. L. Coomber,
    6. E. R. Dufficy,
    7. A. E. Beenken,
    8. J. C. Lee,
    9. S. Clare,
    10. A. O. Speak, et al
    . 2019. EROS/CYBC1 mutations: decreased NADPH oxidase function and chronic granulomatous disease. J. Allergy Clin. Immunol. 143: 782–785.e1.
    OpenUrl
  33. ↵
    1. DeLeo, F. R.,
    2. J. B. Burritt,
    3. L. Yu,
    4. A. J. Jesaitis,
    5. M. C. Dinauer,
    6. W. M. Nauseef
    . 2000. Processing and maturation of flavocytochrome b558 include incorporation of heme as a prerequisite for heterodimer assembly. J. Biol. Chem. 275: 13986–13993.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Thomas, D. C.,
    2. S. Clare,
    3. J. M. Sowerby,
    4. M. Pardo,
    5. J. K. Juss,
    6. D. A. Goulding,
    7. L. van der Weyden,
    8. D. Storisteanu,
    9. A. Prakash,
    10. M. Espéli, et al
    . 2017. Eros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity. J. Exp. Med. 214: 1111–1128.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. McCaffrey, R. L.,
    2. L. A. Allen
    . 2006. Francisella tularensis LVS evades killing by human neutrophils via inhibition of the respiratory burst and phagosome escape. J. Leukoc. Biol. 80: 1224–1230.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Gordon, S.
    2016. Phagocytosis: an immunobiologic process. Immunity 44: 463–475.
    OpenUrl
  37. ↵
    1. Kaufmann, S. H. E.,
    2. A. Dorhoi
    . 2016. Molecular determinants in phagocyte-bacteria interactions. Immunity 44: 476–491.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Babior, B. M.,
    2. R. S. Kipnes,
    3. J. T. Curnutte
    . 1973. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J. Clin. Invest. 52: 741–744.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Baehner, R. L.,
    2. S. K. Murrmann,
    3. J. Davis,
    4. R. B. Johnston Jr.
    . 1975. The role of superoxide anion and hydrogen peroxide in phagocytosis-associated oxidative metabolic reactions. J. Clin. Invest. 56: 571–576.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Johnston, R. B. Jr..,
    2. B. B. Keele Jr..,
    3. H. P. Misra,
    4. J. E. Lehmeyer,
    5. L. S. Webb,
    6. R. L. Baehner,
    7. K. V. RaJagopalan
    . 1975. The role of superoxide anion generation in phagocytic bactericidal activity. Studies with normal and chronic granulomatous disease leukocytes. J. Clin. Invest. 55: 1357–1372.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Rosen, H.,
    2. S. J. Klebanoff
    . 1979. Bactericidal activity of a superoxide anion-generating system. A model for the polymorphonuclear leukocyte. J. Exp. Med. 149: 27–39.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Weiss, S. J.,
    2. R. Klein,
    3. A. Slivka,
    4. M. Wei
    . 1982. Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J. Clin. Invest. 70: 598–607.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Green, J. N.,
    2. A. J. Kettle,
    3. C. C. Winterbourn
    . 2014. Protein chlorination in neutrophil phagosomes and correlation with bacterial killing. Free Radic. Biol. Med. 77: 49–56.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Kutter, D.,
    2. P. Devaquet,
    3. G. Vanderstocken,
    4. J. M. Paulus,
    5. V. Marchal,
    6. A. Gothot
    . 2000. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit? Acta Haematol. 104: 10–15.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Chapman, A. L.,
    2. M. B. Hampton,
    3. R. Senthilmohan,
    4. C. C. Winterbourn,
    5. A. J. Kettle
    . 2002. Chlorination of bacterial and neutrophil proteins during phagocytosis and killing of Staphylococcus aureus. J. Biol. Chem. 277: 9757–9762.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Segal, A. W.,
    2. R. C. Garcia,
    3. A. M. Harper,
    4. J. P. Banga
    . 1983. Iodination by stimulated human neutrophils. Studies on its stoichiometry, subcellular localization and relevance to microbial killing. Biochem. J. 210: 215–225.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Lock, R.,
    2. C. Dahlgren,
    3. M. Lindén,
    4. O. Stendahl,
    5. A. Svensbergh,
    6. L. Ohman
    . 1990. Neutrophil killing of two type 1 fimbria-bearing Escherichia coli strains: dependence on respiratory burst activation. Infect. Immun. 58: 37–42.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Levine, A. P.,
    2. M. R. Duchen,
    3. S. de Villiers,
    4. P. R. Rich,
    5. A. W. Segal
    . 2015. Alkalinity of neutrophil phagocytic vacuoles is modulated by HVCN1 and has consequences for myeloperoxidase activity. PLoS One 10: e0125906.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Segal, A. W.
    2016. NADPH oxidases as electrochemical generators to produce ion fluxes and turgor in fungi, plants and humans. Open Biol. 6: 160028.
    OpenUrlCrossRefPubMed
  50. ↵
    1. Ketterer, S.,
    2. A. Gomez-Auli,
    3. L. E. Hillebrand,
    4. A. Petrera,
    5. A. Ketscher,
    6. T. Reinheckel
    . 2017. Inherited diseases caused by mutations in cathepsin protease genes. FEBS J. 284: 1437–1454.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Hampton, M. B.,
    2. A. J. Kettle,
    3. C. C. Winterbourn
    . 1998. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 92: 3007–3017.
    OpenUrlFREE Full Text
    1. Slauch, J. M.
    2011. How does the oxidative burst of macrophages kill bacteria? Still an open question. Mol. Microbiol. 80: 580–583.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Winterbourn, C. C.,
    2. A. J. Kettle
    . 2013. Redox reactions and microbial killing in the neutrophil phagosome. Antioxid. Redox Signal. 18: 642–660.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Brinkmann, V.,
    2. U. Reichard,
    3. C. Goosmann,
    4. B. Fauler,
    5. Y. Uhlemann,
    6. D. S. Weiss,
    7. Y. Weinrauch,
    8. A. Zychlinsky
    . 2004. Neutrophil extracellular traps kill bacteria. Science 303: 1532–1535.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Brinkmann, V.
    2018. Neutrophil extracellular traps in the second decade. J. Innate Immun. 10: 414–421.
    OpenUrl
    1. Kumar, S.,
    2. E. Gupta,
    3. S. Kaushik,
    4. A. Jyoti
    . 2018. Neutrophil extracellular traps: formation and involvement in disease progression. Iran. J. Allergy Asthma Immunol. 17: 208–220.
    OpenUrl
    1. Law, S. M.,
    2. R. D. Gray
    . 2017. Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: a review. J. Inflamm. (Lond.) 14: 29.
    OpenUrl
  55. ↵
    1. Papayannopoulos, V.
    2018. Neutrophil extracellular traps in immunity and disease. Nat. Rev. Immunol. 18: 134–147.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Fuchs, T. A.,
    2. U. Abed,
    3. C. Goosmann,
    4. R. Hurwitz,
    5. I. Schulze,
    6. V. Wahn,
    7. Y. Weinrauch,
    8. V. Brinkmann,
    9. A. Zychlinsky
    . 2007. Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176: 231–241.
    OpenUrlAbstract/FREE Full Text
  57. ↵
    1. Delgado-Rizo, V.,
    2. M. A. Martínez-Guzmán,
    3. L. Iñiguez-Gutierrez,
    4. A. García-Orozco,
    5. A. Alvarado-Navarro,
    6. M. Fafutis-Morris
    . 2017. Neutrophil extracellular traps and its implications in inflammation: an overview. Front. Immunol. 8: 81.
    OpenUrlCrossRefPubMed
    1. Jorch, S. K.,
    2. P. Kubes
    . 2017. An emerging role for neutrophil extracellular traps in noninfectious disease. Nat. Med. 23: 279–287.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Van Avondt, K.,
    2. D. Hartl
    . 2018. Mechanisms and disease relevance of neutrophil extracellular trap formation. Eur. J. Clin. Invest. 48(Suppl. 2): e12919.
    OpenUrl
  59. ↵
    1. Sollberger, G.,
    2. D. O. Tilley,
    3. A. Zychlinsky
    . 2018. Neutrophil extracellular traps: the biology of chromatin externalization. Dev. Cell 44: 542–553.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Bianchi, M.,
    2. M. J. Niemiec,
    3. U. Siler,
    4. C. F. Urban,
    5. J. Reichenbach
    . 2011. Restoration of anti-Aspergillus defense by neutrophil extracellular traps in human chronic granulomatous disease after gene therapy is calprotectin-dependent. J. Allergy Clin. Immunol. 127: 1243–52.e7.
    OpenUrlCrossRefPubMed
    1. Gazendam, R. P.,
    2. J. L. van Hamme,
    3. A. T. Tool,
    4. M. Hoogenboezem,
    5. J. M. van den Berg,
    6. J. M. Prins,
    7. L. Vitkov,
    8. F. L. van de Veerdonk,
    9. T. K. van den Berg,
    10. D. Roos,
    11. T. W. Kuijpers
    . 2016. Human neutrophils use different mechanisms to kill Aspergillus fumigatus conidia and hyphae: evidence from phagocyte defects. J. Immunol. 196: 1272–1283.
    OpenUrlAbstract/FREE Full Text
  61. ↵
    1. Kenny, E. F.,
    2. A. Herzig,
    3. R. Krüger,
    4. A. Muth,
    5. S. Mondal,
    6. P. R. Thompson,
    7. V. Brinkmann,
    8. H. V. Bernuth,
    9. A. Zychlinsky
    . 2017. Diverse stimuli engage different neutrophil extracellular trap pathways. Elife 6: e24437.
    OpenUrlCrossRef
  62. ↵
    1. Björnsdottir, H.,
    2. A. Welin,
    3. E. Michaëlsson,
    4. V. Osla,
    5. S. Berg,
    6. K. Christenson,
    7. M. Sundqvist,
    8. C. Dahlgren,
    9. A. Karlsson,
    10. J. Bylund
    . 2015. Neutrophil NET formation is regulated from the inside by myeloperoxidase-processed reactive oxygen species. Free Radic. Biol. Med. 89: 1024–1035.
    OpenUrlCrossRefPubMed
  63. ↵
    1. Metzler, K. D.,
    2. T. A. Fuchs,
    3. W. M. Nauseef,
    4. D. Reumaux,
    5. J. Roesler,
    6. I. Schulze,
    7. V. Wahn,
    8. V. Papayannopoulos,
    9. A. Zychlinsky
    . 2011. Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. Blood 117: 953–959.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Bylund, J.,
    2. K. L. MacDonald,
    3. K. L. Brown,
    4. P. Mydel,
    5. L. V. Collins,
    6. R. E. Hancock,
    7. D. P. Speert
    . 2007. Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B. Eur. J. Immunol. 37: 1087–1096.
    OpenUrlCrossRefPubMed
  65. ↵
    1. Meissner, F.,
    2. R. A. Seger,
    3. D. Moshous,
    4. A. Fischer,
    5. J. Reichenbach,
    6. A. Zychlinsky
    . 2010. Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous disease. Blood 116: 1570–1573.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. van Bruggen, R.,
    2. M. Y. Köker,
    3. M. Jansen,
    4. M. van Houdt,
    5. D. Roos,
    6. T. W. Kuijpers,
    7. T. K. van den Berg
    . 2010. Human NLRP3 inflammasome activation is Nox1-4 independent. Blood 115: 5398–5400.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Brown, K. L.,
    2. J. Bylund,
    3. K. L. MacDonald,
    4. G. X. Song-Zhao,
    5. M. R. Elliott,
    6. R. Falsafi,
    7. R. E. Hancock,
    8. D. P. Speert
    . 2008. ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease. Clin. Immunol. 129: 90–102.
    OpenUrlCrossRefPubMed
    1. Hatanaka, E.,
    2. B. T. Carvalho,
    3. A. Condino-Neto,
    4. A. Campa
    . 2004. Hyperresponsiveness of neutrophils from gp 91phox deficient patients to lipopolysaccharide and serum amyloid A. Immunol. Lett. 94: 43–46.
    OpenUrlCrossRefPubMed
    1. Lekstrom-Himes, J. A.,
    2. D. B. Kuhns,
    3. W. G. Alvord,
    4. J. I. Gallin
    . 2005. Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease. J. Immunol. 174: 411–417.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Sundqvist, M.,
    2. K. Christenson,
    3. H. Björnsdottir,
    4. V. Osla,
    5. A. Karlsson,
    6. C. Dahlgren,
    7. D. P. Speert,
    8. A. Fasth,
    9. K. L. Brown,
    10. J. Bylund
    . 2017. Elevated mitochondrial reactive oxygen species and cellular redox imbalance in human NADPH-oxidase-deficient phagocytes. Front. Immunol. 8: 1828.
    OpenUrl
  69. ↵
    1. van de Veerdonk, F. L.,
    2. S. P. Smeekens,
    3. L. A. Joosten,
    4. B. J. Kullberg,
    5. C. A. Dinarello,
    6. J. W. van der Meer,
    7. M. G. Netea
    . 2010. Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc. Natl. Acad. Sci. USA 107: 3030–3033.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Bylund, J.,
    2. H. Björnsdottir,
    3. M. Sundqvist,
    4. A. Karlsson,
    5. C. Dahlgren
    . 2014. Measurement of respiratory burst products, released or retained, during activation of professional phagocytes. Methods Mol. Biol. 1124: 321–338.
    OpenUrlCrossRefPubMed
  71. ↵
    1. van Pelt, L. J.,
    2. R. van Zwieten,
    3. R. S. Weening,
    4. D. Roos,
    5. A. J. Verhoeven,
    6. B. G. Bolscher
    . 1996. Limitations on the use of dihydrorhodamine 123 for flow cytometric analysis of the neutrophil respiratory burst. J. Immunol. Methods 191: 187–196.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Wardman, P.
    2007. Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: progress, pitfalls, and prospects. Free Radic. Biol. Med. 43: 995–1022.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Albrett, A. M.,
    2. L. V. Ashby,
    3. N. Dickerhof,
    4. A. J. Kettle,
    5. C. C. Winterbourn
    . 2018. Heterogeneity of hypochlorous acid production in individual neutrophil phagosomes revealed by a rhodamine-based probe. J. Biol. Chem. 293: 15715–15724.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Lundqvist, H.,
    2. C. Dahlgren
    . 1996. Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils. Free Radic. Biol. Med. 20: 785–792.
    OpenUrlCrossRefPubMed
  75. ↵
    1. Erard, M.,
    2. S. Dupré-Crochet,
    3. O. Nüße
    . 2018. Biosensors for spatiotemporal detection of reactive oxygen species in cells and tissues. Am. J. Physiol. Regul. Integr. Comp. Physiol. 314: R667–R683.
    OpenUrl
  76. ↵
    1. Nauseef, W. M.
    2014. Identification and quantitation of superoxide anion: essential steps in elucidation of the phagocyte “respiratory burst”. J. Immunol. 193: 5357–5358.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Immunology: 202 (11)
The Journal of Immunology
Vol. 202, Issue 11
1 Jun 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Intracellular Neutrophil Oxidants: From Laboratory Curiosity to Clinical Reality
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Intracellular Neutrophil Oxidants: From Laboratory Curiosity to Clinical Reality
Claes Dahlgren, Anna Karlsson, Johan Bylund
The Journal of Immunology June 1, 2019, 202 (11) 3127-3134; DOI: 10.4049/jimmunol.1900235

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Intracellular Neutrophil Oxidants: From Laboratory Curiosity to Clinical Reality
Claes Dahlgren, Anna Karlsson, Johan Bylund
The Journal of Immunology June 1, 2019, 202 (11) 3127-3134; DOI: 10.4049/jimmunol.1900235
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Introduction
    • Conclusions
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • γδ T, NKT, and MAIT Cells During Evolution: Redundancy or Specialized Functions?
  • Innate and Innate-like Effector Lymphocytes in Health and Disease
  • Genomic and Transcriptional Mechanisms Governing Innate-like T Lymphocyte Development
Show more BRIEF REVIEWS

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606